MA27934A1 - Sel d'acide (2s,4s)-4-fluoro-1-(4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl)-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes cristallines anhydres - Google Patents

Sel d'acide (2s,4s)-4-fluoro-1-(4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl)-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes cristallines anhydres

Info

Publication number: MA27934A1
Authority: MA; Morocco
Prior art keywords: fluoro; pyrrolidinecarbonitrile; phenylalanyl; fluorophenyl; beta
Prior art date: 2003-07-21

Application number

MA28758A

Other languages

English (en)

Inventor

Igo H David

Johnson R Paul

Patterson E Daniel

Sab Randhawa Amarjit

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-21

Filing date

2006-01-27

Publication date

2006-06-01

2006-01-27 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2006-06-01 Publication of MA27934A1 publication Critical patent/MA27934A1/fr

Links

JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 title 2
-1 4-FLUOROPHENYL Chemical class 0.000 title 1
MSCWUTTUQLYJFT-QMBKNIKNSA-N (2s,4s)-1-[(2s)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 MSCWUTTUQLYJFT-QMBKNIKNSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Virology (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Neurology (AREA)

MA28758A 2003-07-21 2006-01-27 Sel d'acide (2s,4s)-4-fluoro-1-(4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl)-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes cristallines anhydres MA27934A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US48890203P	2003-07-21	2003-07-21

Publications (1)

Publication Number	Publication Date
MA27934A1 true MA27934A1 (fr)	2006-06-01

Family

ID=34102801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA28758A MA27934A1 (fr)	2003-07-21	2006-01-27	Sel d'acide (2s,4s)-4-fluoro-1-(4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl)-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes cristallines anhydres

Country Status (17)

Country	Link
US (1)	US7462641B2 (fr)
EP (1)	EP1654226B1 (fr)
JP (1)	JP2006528187A (fr)
KR (1)	KR20060037391A (fr)
CN (1)	CN1852893A (fr)
AT (1)	ATE411980T1 (fr)
AU (1)	AU2004259741A1 (fr)
BR (1)	BRPI0412763A (fr)
CA (1)	CA2532397A1 (fr)
DE (1)	DE602004017325D1 (fr)
IL (1)	IL173059A0 (fr)
MA (1)	MA27934A1 (fr)
MX (1)	MXPA06000725A (fr)
NO (1)	NO20060399L (fr)
RU (1)	RU2006106429A (fr)
WO (1)	WO2005009956A1 (fr)
ZA (1)	ZA200600605B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100869616B1 (ko)	2004-05-12	2008-11-21	화이자 프로덕츠 인코포레이티드	프롤린 유도체 및 그의 다이펩티딜 펩티다제－ｉｖ저해제로서의 용도
DOP2006000008A (es)	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
AU2006239929B2 (en)	2005-04-22	2011-11-03	Alantos Pharmaceuticals Holding, Inc.	Dipeptidyl peptidase-IV inhibitors
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2008126793A1 (fr)	2007-04-05	2008-10-23	Nippon Shokubai Co., Ltd.	Absorbant d'eau granulaire comprenant une résine d'absorption d'eau en tant que composant principal
PE20090938A1 (es)	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
JP5989965B2 (ja) *	2008-01-08	2016-09-07	メルクシャープエンドドームリミテッド	２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
JP5611846B2 (ja) *	2008-03-12	2014-10-22	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	置換ヘテロ環縮合ガンマ−カルボリン類固体
EP2108960A1 (fr)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
WO2010047982A1 (fr)	2008-10-22	2010-04-29	Merck Sharp & Dohme Corp.	Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
BRPI1008560B1 (pt)	2009-02-13	2021-08-31	Boehringer Ingelheim International Gmbh	Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
US8895596B2 (en)	2010-02-25	2014-11-25	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
AU2011237775A1 (en)	2010-04-06	2012-11-22	Arena Pharmaceuticals, Inc.	Modulators of the GPR119 receptor and the treatment of disorders related thereto
PH12013500547A1 (en)	2010-09-22	2013-06-10	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112013021236B1 (pt)	2011-02-25	2021-05-25	Merck Sharp & Dohme Corp	composto derivado de benzimidazol, e, composição
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en)	2011-04-19	2014-03-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en)	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (fr)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012170702A1 (fr)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2013155504A1 (fr)	2012-04-14	2013-10-17	Intra-Cellular Therapies, Inc.	Nouveaux procédés
US9527875B2 (en)	2012-08-02	2016-12-27	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2014074668A1 (fr)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
RU2015140066A (ru)	2013-02-22	2017-03-30	Мерк Шарп И Доум Корп.	Противодиабетические бициклические соединения
WO2014139388A1 (fr)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
HUE053159T2 (hu)	2013-03-15	2021-06-28	Intra Cellular Therapies Inc	Szerves vegyületek
WO2015051496A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Composés tricycliques antidiabétiques
IL305990B2 (en)	2013-12-03	2025-12-01	Intra Cellular Therapies Inc	Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder
MX365969B (es)	2014-04-04	2019-06-21	Intra Cellular Therapies Inc	Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
RU2016143091A (ru)	2014-04-04	2018-05-08	Интра-Селлулар Терапиз, Инк.	Органические соединения
EA201791982A1 (ru)	2015-03-09	2020-02-17	Интекрин Терапьютикс, Инк.	Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CN108883111B (zh)	2016-01-26	2021-10-08	细胞内治疗公司	有机化合物
PL3407889T3 (pl)	2016-03-25	2021-11-22	Intra-Cellular Therapies, Inc.	Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego
JP2019513143A (ja)	2016-03-28	2019-05-23	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規塩類および結晶
US11014925B2 (en)	2016-03-28	2021-05-25	Intra-Cellular Therapies, Inc.	Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
EP3436083A4 (fr)	2016-03-28	2019-11-27	Intra-Cellular Therapies, Inc.	Nouvelles compositions et méthodes
US11331316B2 (en)	2016-10-12	2022-05-17	Intra-Cellular Therapies, Inc.	Amorphous solid dispersions
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (fr)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Composés de spirochromane antidiabétiques
US10906906B2 (en)	2016-12-29	2021-02-02	Intra-Cellular Therapies, Inc.	Organic compounds
US10961245B2 (en)	2016-12-29	2021-03-30	Intra-Cellular Therapies, Inc.	Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
IL268970B2 (en)	2017-03-24	2023-12-01	Intra Cellular Therapies Inc	Oral transmucosal formulations of substituted heterocycle fused gamma carbolines
AU2018249822A1 (en)	2017-04-03	2019-10-31	Coherus Biosciences Inc.	PPArgamma agonist for treatment of progressive supranuclear palsy
JP7224333B2 (ja)	2017-07-26	2023-02-17	イントラ－セルラー・セラピーズ・インコーポレイテッド	有機化合物
JP7223742B2 (ja)	2017-07-26	2023-02-16	イントラ－セルラー・セラピーズ・インコーポレイテッド	有機化合物
CN111107847A (zh)	2017-09-26	2020-05-05	细胞内治疗公司	新的盐和晶体
CN109867674A (zh) *	2017-12-05	2019-06-11	上海度德医药科技有限公司	一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型
AU2019240226B2 (en)	2018-03-23	2024-11-28	Intra-Cellular Therapies, Inc.	Organic compounds
IL321985A (en)	2018-06-06	2025-09-01	Intra Cellular Therapies Inc	New salts and crystals
WO2019237037A1 (fr)	2018-06-08	2019-12-12	Intra-Cellular Therapies, Inc.	Nouvelles méthodes
CA3106447A1 (fr)	2018-06-11	2019-12-19	Intra-Cellular Therapies, Inc.	Synthese de gamma-carbolines fusionnees a heterocycles substitues
EP3843729A4 (fr)	2018-08-29	2022-06-01	Intra-Cellular Therapies, Inc.	Nouvelles compositions et méthodes
CA3108558A1 (fr)	2018-08-31	2020-03-05	Intra-Cellular Therapies, Inc.	Nouvelles methodes
CN112584837A (zh)	2018-08-31	2021-03-30	细胞内治疗公司	新方法
US20210347758A1 (en)	2018-10-03	2021-11-11	Tesaro, Inc.	Crystalline Forms of Niraparib Freebase
JP7673040B2 (ja)	2019-07-07	2025-05-08	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規方法
US12414948B2 (en)	2022-05-18	2025-09-16	Intra-Cellular Therapies, Inc.	Methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2296979T3 (es) *	2001-06-27	2008-05-01	Smithkline Beecham Corporation	Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.

2004
- 2004-07-19 AU AU2004259741A patent/AU2004259741A1/en not_active Abandoned
- 2004-07-19 JP JP2006521180A patent/JP2006528187A/ja active Pending
- 2004-07-19 US US10/565,294 patent/US7462641B2/en not_active Expired - Fee Related
- 2004-07-19 AT AT04778669T patent/ATE411980T1/de not_active IP Right Cessation
- 2004-07-19 CN CNA2004800270931A patent/CN1852893A/zh active Pending
- 2004-07-19 CA CA002532397A patent/CA2532397A1/fr not_active Abandoned
- 2004-07-19 RU RU2006106429/04A patent/RU2006106429A/ru not_active Application Discontinuation
- 2004-07-19 BR BRPI0412763-3A patent/BRPI0412763A/pt not_active Application Discontinuation
- 2004-07-19 EP EP04778669A patent/EP1654226B1/fr not_active Expired - Lifetime
- 2004-07-19 DE DE602004017325T patent/DE602004017325D1/de not_active Expired - Fee Related
- 2004-07-19 KR KR1020067001464A patent/KR20060037391A/ko not_active Ceased
- 2004-07-19 MX MXPA06000725A patent/MXPA06000725A/es unknown
- 2004-07-19 WO PCT/US2004/023263 patent/WO2005009956A1/fr not_active Ceased
2006
- 2006-01-10 IL IL173059A patent/IL173059A0/en unknown
- 2006-01-20 ZA ZA200600605A patent/ZA200600605B/en unknown
- 2006-01-25 NO NO20060399A patent/NO20060399L/no not_active Application Discontinuation
- 2006-01-27 MA MA28758A patent/MA27934A1/fr unknown

Also Published As

Publication number	Publication date
CN1852893A (zh)	2006-10-25
MXPA06000725A (es)	2006-03-30
AU2004259741A1 (en)	2005-02-03
US20070066677A1 (en)	2007-03-22
RU2006106429A (ru)	2006-08-27
JP2006528187A (ja)	2006-12-14
CA2532397A1 (fr)	2005-02-03
EP1654226B1 (fr)	2008-10-22
BRPI0412763A (pt)	2006-09-26
ZA200600605B (en)	2007-05-30
US7462641B2 (en)	2008-12-09
IL173059A0 (en)	2006-06-11
NO20060399L (no)	2006-02-17
WO2005009956A1 (fr)	2005-02-03
KR20060037391A (ko)	2006-05-03
ATE411980T1 (de)	2008-11-15
DE602004017325D1 (de)	2008-12-04
EP1654226A1 (fr)	2006-05-10

Publication	Publication Date	Title
MA27934A1 (fr)	2006-06-01	Sel d'acide (2s,4s)-4-fluoro-1-(4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl)-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes cristallines anhydres
EA200400026A1 (ru)	2004-04-29	Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтические применения и вещества для их синтеза
NO20063486L (no)	2006-08-29	Bicykloesterderivater
BR0113286A (pt)	2003-09-09	Pirazóis substituìdos
SV2003001144A (es)	2003-03-18	FORMAS CRISTALINAS DE LA SAL DE CALCIO DEL ACIDO [R-(R,R)]-2-(4-FLUOROFENIL)-ß,ô-DIHIDROXI-5-(1-METILETIL)-3-FENIL-4[(FENILAMINO)CARBONIL]-1H-PIRROL-1-HEPTANOICO (2:1) REF. PC430-01FJT
DK0528858T3 (da)	1997-07-28	Inhibitorer af dipeptidyl-aminopeptidase type IV
BG101284A (bg)	1998-03-31	Съединения и методи за лечение на рак
BR0113161A (pt)	2004-04-06	Arilóxi piperidinas não imidazóis
DE69719755D1 (de)	2003-04-17	Polymorphe verbindungen
ES2171723T3 (es)	2002-09-16	3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
EE200300168A (et)	2003-06-16	Tripeptidüülpeptidaasi inhibiitorid, nende valmistamine ja kasutamine ravimina ning neid sisaldav farmatseutiline kompositsioon
EA200400708A1 (ru)	2004-10-28	Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
DK1309562T3 (da)	2008-08-11	4-Alkoxycyclohexan-1-aminocarboxylsyreestere og fremgangsmåde til fremstilling deraf
EA200100807A1 (ru)	2002-08-29	Производные алкинилсодержащих гидроксамовых кислот и их применение в качестве ингибиторов tace
EA200300579A1 (ru)	2003-12-25	Соединение лактама
DE69632876D1 (de)	2004-08-12	2-Amino-Benzoxazinone zur Behandlung von viralen Infektionen
DE59910956D1 (de)	2004-12-02	Medizinische Verwendung von Mechanismus-orientierten Inhibitoren der Dipeptidylpeptidase I
ES2076838T3 (es)	1995-11-01	Nuevo derivado de la isoindolinona, su preparacion y las composiciones farmaceuticas que le contienen.
EA200400751A1 (ru)	2004-12-30	Применение дезоксипеганина для лечения клинической депрессии
GEP20063936B (en)	2006-10-10	New anhydrous crystalline forms of gabapentin
BR0311590A (pt)	2005-05-10	Agonistas de brs-3 não-peptìdicos
DK1178985T3 (da)	2003-07-28	Substituerede thienocycloalk(en)ylamino-1,3,5-triaziner
PT1244614E (pt)	2004-10-29	Inibidores de triptase
BRPI0409333A (pt)	2006-04-25	processo para a preparação de fenilamida do ácido 5-(4-fluorofenil)-1-[2-((2r,4r)-4-hidróxi-6-oxo-tetrahid ro-piran-2-il)etil]-2-isopropil-4-fenil-1h-pirrol-3-carb oxìlico
ATE440952T1 (de)	2009-09-15	Identifzierung der cytotoxischen wirksamkeit von die tinte von aplysia punctata